申请人:Merck & Co., Inc.
公开号:US05763361A1
公开(公告)日:1998-06-09
The novel compounds of the present invention are those of structural formula I: ##STR1## or a pharmaceutically acceptable salt, or stereoisomer thereof, which are inhibitors of 5.alpha.-reductase, particularly 5.alpha.-reductase type 1. The compounds of formula I are useful in the systemic, including oral, or parenteral or topical treatment of hyperandrogenic conditions such as acne vulgaris, seborrhea, androgenic alopecia which includes female and male pattern baldness, female hirsutism, benign prostafic hyperplasia, and the prevention and treatment of prostatic carcinoma, as well as in the treatment of prostatitis. Methods of using the compounds of formula I for the treatment of hyperandrogenic conditions such as acne vulgaris, seborrhea, androgenic alopecia, male pattern baldness, female hirsutism, benign prostatic hyperplasia, and the prevention and treatment of prostatic carcinoma, as well as the treatment of prostatitis are provided, as well as pharmaceutical compositions for the compounds of formula I. The use of compounds of formula I in combination with other, active agents, for example with a 5.alpha.-reductase type 2 inhibitor such as finasteride or epristeride, or a potassium channel opener, such as minoxidil, or a retinoic acid or a derivative thereof is also taught, wherein such combinations would be useful in one or more of the above-mentioned methods of treatment or pharmaceutical compositions.
本发明的新化合物为结构式I的化合物:##STR1##或其药学上可接受的盐或立体异构体,它们是5α-还原酶的抑制剂,特别是5α-还原酶类型1。式I的化合物在系统性治疗,包括口服、或者肌肉注射或局部治疗过多雄激素症状如痤疮、脂溢性皮炎、雄激素性脱发包括女性和男性型脱发、女性多毛症、良性前列腺增生以及前列腺癌的预防和治疗,以及前列腺炎的治疗中是有用的。提供了使用式I的化合物治疗过多雄激素症状如痤疮、脂溢性皮炎、雄激素性脱发、男性型脱发、女性多毛症、良性前列腺增生以及前列腺癌的预防和治疗,以及前列腺炎的方法,以及式I的化合物的药物组合。还教授了将式I的化合物与其他活性剂结合使用,例如与5α-还原酶类型2抑制剂如非那雄胺或依普利司特结合使用,或者与钾通道开放剂如米诺地尔结合使用,或者与维甲酸或其衍生物结合使用,这样的组合在上述任一或多种治疗方法或药物组合中是有用的。